Top-Cited Gastroenterology and Hepatology Articles Published Across All Journals Listed in the Web of Science™, Identified by Keyword Search, Ranked From 1 to 50 (List B).

Rankc	Author, Year [Reference]	Title (Journal)	Category	Number of citations	Origin: First author's organisation, location (country)
1	Hurwitz et al, 200479	Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer (New England Journal of Medicine).	Research	5,500	Duke University Medical Center, Durham, North Carolina, (United States).
2	Choo et al, 198980	Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome (Science).	Research	5,227	Chiron Corporation, Emeryville, California, (United States)
3	Pugh et al, 197381	Transection of the oesophagus for bleeding oesophageal varices. (British Journal of Surgery)	Research	4,630	King's College Hospital and Medical School, London, (United Kingdom).
4	Manns et al, 200182	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (Lancet).	Research	4,438	Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, (Germany).
5	Fried et al, 200283	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. (New England Journal of Medicine).	Research	4,363	University of North Carolina, Chapel Hill (United States).
6	Llovet et al, 200884	Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine).	Research	3,355	Barcelona Clínic Liver Cancer Group, Liver Unit, Barcelona, (Spain).
7	Kinzler and Vogelstein, 199685	Lessons from hereditary colorectal cancer (Cell).	Review	3,325	The Johns Hopkins Oncology Center, Baltimore, Maryland (United States).
8	Perna et al, 200186	Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. (Nature).	Research	3,306	Genome Center of Wisconsin, University of Wisconsin, Madison, (United States)
9	Hugot et al, 200187	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. (Nature).	Research	3,185	Fondation Jean Dausset CEPH, Paris, (France).
10	Tomb et al, 199788	The complete genome sequence of the gastric pathogen Helicobacter pylori. (Nature).	Research	3,173	Institute for Genomic Research, Rockville, Maryland 20850, (United Stats).
11	Mazzaferro et al, 199689	Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. (New England Journal of Medicine).	Research	3,154	Department of Surgery, National Cancer Institute, Milan, (Italy).
12	Bruix and Sherman, 200525	Management of hepatocellular carcinoma (Hepatology)	Practice guideline	2,959	University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, (Spain).
13	Kuo et al, 198990	An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. (Science).	Research	2,951	Chiron Corporation, Emeryville, California, (United States).
14	Ogura et al, 200191	A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. (Nature).	Research	2,917	The University of Michigan Medical School, Ann Arbor, Michigan, (United States).
15	Parsonnet et al, 199192	Helicobacter pylori infection and the risk of gastric carcinoma. (New England Journal of Medicine).	Research	2,913	Department of Medicine, Stanford University School of Medicine, California, (United States).
16	Knodell et al, 198126	Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. (Hepatology).	Research	2,890	Gastroenterology Section, Veterans Administration Medical Center, Minneapolis, Minnesota, (United States).
17	Dixon et al, 199693	Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. (The American Journal of Surgical Pathology).	Article	2,874	University of Leeds, (United Kingdom).
18	Burris et al, 199794	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. (Journal of Clinical Oncology).	Research	2,830	Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, (United States).
19	Cunningham et al, 200495	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (New England Journal of Medicine).	Research	2,772	Royal Marsden Hospital, London, (United Kingdom).
20	Hayashi et al, 200196	Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. (DNA Research).	Research	2,755	Department of Microbiology, Miyazaki Medical College, Kiyotake, (Japan).
21	Feder et al, 199697	A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. (Nature Genetics).	Research	2,744	Mercator Genetics, Inc., Menlo Park, California, (United States)
22	McHutchison et at, 199898	Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. (New England Journal of Medicine).	Research	2,639	Division of Gastroenterology- Hepatology, Scripps Clinic and Research Foundation, La Jolla, California, (United States).
23	Groux et al, 199799	A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. (Nature)	Research	2,627	DNAX Research Institute of Molecular and Cellular Biology, Inc., Human Immunology Department, Palo Alto, California, (United States).
24	Morin et al, 1997100	Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. (Science)	Research	2,613	Howard Hughes Medical Institute and Johns Hopkins Oncology Center, Baltimore, Maryland, (United States).
25	Ishak et al, 199527	Histological grading and staging of chronic hepatitis. (Journal of Hepatology).	Article	2,603	Armed Forces Institute of Pathology, Washington, (United States).
26	Nataro and Kaper, 1998101	Diarrheagenic Escherichia coli. (Clinical Microbiology Reviews).	Review	2,568	Department of Medicine, University of Maryland School of Medicine, Baltimore, (United States).
27	Boland et al, 1998102	A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. (Cancer Research)	Review	2,559	University of California, San Diego, (United States).
28	Bruix et al, 200128	Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver ( Journal of Hepatology).	Article	2,467	Liver Unit, Digestive Disease Institute, Hospital Clinic, IDIBAPS, Barcelona, Catalonia, (Spain).
29	Llovet et al, 2003103	Hepatocellular carcinoma. (Lancet).	Review	2,401	Barcelona-Clínic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, University of Barcelona, Barcelona, (Spain).
30	Demetri et al, 2002104	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine).	Research	2,383	Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA, (United States).
31	Winawer et al, 1993105	Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. (New England Journal of Medicine).	Research	2,355	Gastroenterology and Nutrition Service, Memorial Sloan-Kettering Cancer Center, New York, (United States).
32	Aaltonen et al, 1993.106	Clues to the pathogenesis of familial colorectal cancer. (Science).	Research	2,337	Department of Medical Genetics, University of Helsinki, (Finland).
33	Bombardier et al, 2000107	Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. (New England Journal of Medicine).	Research	2,315	Institute for Work and Health, Mount Sinai Hospital, and the University Health Network, Toronto, ON, (Canada).
34	Best et al, 197629	Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study (Gastroenterology)	Research	2,263	University of Colorado Medical Center, Denver, Colorado, (United States)
35	Thiebaut et al, 1987108	Cellular localization of the multidrug-resistance gene product P- glycoprotein in normal human tissues (Proceedings of the National Academy of Sciences of the United States of America).	Research	2,245	Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD, (United States).
36	Kleiner et al, 200530	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. (Hepatology)	Research	2,222	Laboratory of Pathology, National Cancer Institute, Bethesda, MD, (United States)
37	Fishel et al, 1993109	The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. (Cell).	Research	2,207	Department of Microbiology and Molecular Genetics Markey Center for Molecular Genetics University of Vermont Medical School Burlington, (United States)
38	Angulo, 2002110	Nonalcoholic fatty liver disease. (New England Journal of Medicine).	Review	2,202	Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, (United States).
39	Targan et al, 1997111	A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. (New England Journal of Medicine).	Research	2,173	Cedars-Sinai Medical Center, Los Angeles, California (United States).
40	Stocker et al, 1987112	Bilirubin is an antioxidant of possible physiological importance (Science).	Research	2147	University of California, Berkeley, Department of Biochemistry, Berkeley, California (United States).
41	Podolsky, 2002113	Inflammatory bowel disease. (New England Journal of Medicine).	Review	2,118	Gastrointestinal unit and the Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, (United States).
42	de Gramont et al, 2000114	Leucovorin and fluorouracil with or without oxaliplatin as first- line treatment in advanced colorectal cancer. (Journal of Clinical Oncology).	Research	2,094	Service de Médecine Interne-Oncologie, Hôpital Saint-Antoine, Paris, (France).
43	Hadziyannis et al, 2004115	Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (Annals of Internal Medicine)	Research	2,063	Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, (Greece).
44	Mandel et al, 1993116	Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. (New England Journal of Medicine).	Research	2,047	Division of Environmental and Occupational Health, University of Minnesota, Minneapolis, (United States).
45	Saltz et al, 2000117	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. (New England Journal of Medicine).	Research	2,040	Memorial Sloan-Kettering Cancer Center, New York, (united States).
46	Uemura et al, 2001118	Helicobacter pylori infection and the development of gastric cancer. (New England Journal of Medicine).	Research	2,039	Department of Gastroenterology, Kure Kyosai Hospital, Kure City, (Japan)
47	Desmet et al, 199431	Classification of chronic hepatitis: diagnosis, grading and staging. (Hepatology).	Review	2038	Department of Pathology, Catholic University of Leuven, (Belgium).
48	Beasley et al, 1981119	Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. (Lancet).	Research	2,029	University Washington Medical Research Unit, Taipei, Taiwan.
49	El-Serag and Rudolph, 200732	Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology).	Review	2,028	Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine, Houston, Texas, (United States)
50	Eberhart et al, 199433	Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. (Gastroenterology)	Research	1,929	Vanderbilt University Medical Center, Nashville, Tennessee (United States).